High-dose chemotherapy supported with autologous hematopoietic stem cell transplant in small-cell lung cancer
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 1
Abstract
Small-cell lung cancer provides clinicians with a paradox. Although it is a highly chemosensitive disease, it remains ultimately fatal for the majority of patients. The majority of patients respond to first-line chemotherapy, but such responses are of relatively short duration. More than 90% of patients die from the disease due to the development of a drug resistance. Escalating the dose of conventional chemotherapy and treatment intensification with autologous bone marrow or peripheral blood stem cell transplant is a theoretical method to overcome the drug resistance. The efficacy of high-dose therapy with stem cells support as an early component of treatment produced the results comparable to those achieved with standard chemotherapy. High-dose therapy with the substitution of peripheral blood stem cells as late intensification after the standard treatment was tested more commonly, particularly in a selected population of younger patients with limited disease, better performance status and less frequent comorbid conditions. Even in this more favourable subset, the survival benefits were not clear despite reduced treatment-related mortality. Up to date, the superiority of an intensified treatment strategy in small-cell lung cancer has not been demonstrated in a convincing way and further controlled trials are necessary to clarify its role, since major problems such as the selection of patients, doses and timing of chemotherapy and radiotherapy remain unsolved. The integration of new molecularly targeted agents into research protocols may be appropriate.
Authors and Affiliations
Maciej Krzakowski
Keywords
Related Articles
- EP ID EP144329
- DOI -
- Views 70
- Downloads 0
Receptor VEGFR-2 – cel terapii kierowanej w chorobach nowotworowych
Kluczowym czynnikiem w procesie powstawania nowych naczyń okołonowotworowych jest naczyniowo-śródbłonkowy czynnik wzrostu VEGF (ang. vascular endothelial growth factor). Jednym z jego receptorów jest należący do rodziny...
Irinotecan in chemotherapy of advanced colorectal cancer
Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin, which effectiveness and toxicity have been extensively investigated in colorectal cancer (crc) and in this type of neoplasm it has wide application. Prom...
Aktywność katepsyny D w surowicy krwi i moczu chorych na raka jelita grubego
Katepsyna D [EC 3.4.23.5] jest proteinazą aspartylową. Jest jednym z enzymów kaskady proteolitycznej zaangażowanej w inwazję nowotworową i tworzenie przerzutów. Jej obecność stwierdzono zarówno w tkankach prawidłowych, j...
Clinical significance of apoptotic index in non-smell cell lung cancer
Apoptosis remains a physiological form of cell death, which enables elimination of damaged cells. Apoptosis is also called programmed cell death, because this process is exactly regulated by several genes including P53,...
Przeszczepianie komórek krwiotwórczych od dawców allogenicznych: wyniki leczenia na podstawie doświadczenia Dolnośląskiego Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku
Przeszczepianie macierzystych komórek krwiotwórczych (HSCT) od allogenicznego dawcy jest postępowaniem z wyboru w leczeniu części chorych z ciężkimi niedoborami tkanki krwiotwórczej i nowotworami tego układu. Analiza k...